China's biotech firm Sinovac claimed that a third dose of its Coronavirus (COVID-19) vaccine is 94 per cent effective against the Omicron variant of the COVID-19.
This comes a day after a study found that the two doses of the vaccine failed to generate any detectable antibody response against the fast-spreading variant.
The study was conducted by the company on 20 people who received two shots and another 48 who received three shots. Seven in the first group and 45 in the second tested positive in neutralizing antibodies against the Omicron variant, the company said in a statement to the Global Times.
Sinovac said that the data demonstrated that the administration of a booster shot of its vaccine can effectively enhance the vaccine's neutralizing capacity to the Omicron variant, read the statement.
The company's findings are in contrast with those released on Tuesday in a preprint paper by the HKU researchers.
The university study also examined neutralising antibodies, one arm of immune response that serves as a rough marker for protection against infection.
Of 25 people who received a full two-dose course of CoronaVac, none were found to have detectable levels of neutralising antibodies, according to study author and top infectious disease expert Yuen Kwok-yung and his team.
The Omicron variant, first discovered in early November, has been reported in 77 countries and regions, according to the World Health Organization.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)